Rapport du Mémoire et de la méthode présentée à l’Académie par Mr Hauy pour l’instruction des Aveugles : a digital edition by Ali, Y

“…This is a manuscript report made by members of the Royal Academy of Sciences (Académie royale des sciences) of Paris, France on Valentin Haüy's methods for teaching the Blind.…”

Moscow - Berlin - Paris: Walter Benjamin's intercultural spaces of comparison by Buck, S

“…Bringing together sources from across Europe not only interrogates disciplinary blind spots in Benjamin reception, but also inscribes Benjamin’s thought into an entangled intellectual European history. …”

Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study by Debruyne, F, Koch, G, Boyle, P, Da Silva, F, Gillenwater, J, Hamdy, F, Perrin, P, Teillac, P, Vela-Navarrete, R, Raynaud, J

“…METHODS: Eight hundred and eleven men with symptomatic BPH (international prostdate symptom score, I-PSS > or = 10) were recruited in 11 European countries for a 12-month, double-blind randomized trial. After a 4-week run-in period, 704 patients were randomly assigned to either tamsulosin 0.4 mg per day (N = 354) or Permixon 320 mg per day (N = 350). …”

[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]. by Debruyne, F, Boyle, P, Calais da Silva, F, Gillenwater, J, Hamdy, F, Perrin, P, Teillac, P, Vela-Navarrete, R, Raynaud, J, Schulman, C

“…METHODS: In a 12-month, double-blind, randomized study that showed equivalent efficacy of Permixon 320 mg/day and tamsulosin 0.4 mg/day ("PERMAL study"), 685 BPH patients with IPSS > 10 had been analyzed for efficacy. …”

Evaluation of the clinical benefit of permixon® and tamsulosin in severe BPH patients - PERMAL study subset analysis by Debruyne, F, Boyle, P, Calais Da Silva, F, Gillenwater, J, Hamdy, F, Perrin, P, Teillac, P, Vela-Navarrete, R, Raynaud, J, Schulman, C

“…Methods: In a 12-month, double-blind, randomized study that showed equivalent efficacy of Permixon 320 mg/day and tamsulosin 0.4 mg/day ("PERMAL study"), 685 BPH patients with IPSS ≥ 10 had been analyzed for efficacy. …”

[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. by Debruyne, F, Koch, G, Boyle, P, Da Silva, F, Gillenwater, J, Hamdy, F, Perrin, P, Teillac, P, Vela-Navarrete, R, Raynaud, J

“…METHODS: Eight hundred and eleven men with symptomatic BPH (international prostdate symptom score, I-PSS > or = 10) were recruited in 11 European countries for a 12-month, double-blind randomized trial. After a 4-week run-in period, 704 patients were randomly assigned to either tamsulosin 0.4 mg per day (N = 354) or Permixon 320 mg per day (N = 350). …”